SG11201406336YA - Stem cell microparticles - Google Patents

Stem cell microparticles

Info

Publication number
SG11201406336YA
SG11201406336YA SG11201406336YA SG11201406336YA SG11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA
Authority
SG
Singapore
Prior art keywords
stem cell
cell microparticles
microparticles
stem
cell
Prior art date
Application number
SG11201406336YA
Inventor
John Sinden
Lara Stevanato
Randolph Corteling
Original Assignee
Reneuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1205972.1A external-priority patent/GB201205972D0/en
Priority claimed from GBGB1212848.4A external-priority patent/GB201212848D0/en
Priority claimed from GBGB1302468.2A external-priority patent/GB201302468D0/en
Application filed by Reneuron Ltd filed Critical Reneuron Ltd
Publication of SG11201406336YA publication Critical patent/SG11201406336YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/088—Coculture with; Conditioned medium produced by cells of the nervous system neural stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
SG11201406336YA 2012-04-03 2013-04-03 Stem cell microparticles SG11201406336YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1205972.1A GB201205972D0 (en) 2012-04-03 2012-04-03 Stem cell product
GBGB1212848.4A GB201212848D0 (en) 2012-07-19 2012-07-19 Stem cell product
GBGB1302468.2A GB201302468D0 (en) 2013-02-12 2013-02-12 Stem cell product
PCT/GB2013/050879 WO2013150303A1 (en) 2012-04-03 2013-04-03 Stem cell microparticles

Publications (1)

Publication Number Publication Date
SG11201406336YA true SG11201406336YA (en) 2014-11-27

Family

ID=48095915

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406336YA SG11201406336YA (en) 2012-04-03 2013-04-03 Stem cell microparticles

Country Status (11)

Country Link
US (2) US20150079046A1 (en)
EP (2) EP3470073A1 (en)
JP (5) JP6450673B2 (en)
KR (1) KR101993027B1 (en)
CN (1) CN104321062B (en)
AU (1) AU2013245406B2 (en)
BR (1) BR112014024541A2 (en)
CA (1) CA2868506C (en)
ES (1) ES2691296T3 (en)
SG (1) SG11201406336YA (en)
WO (1) WO2013150303A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683389B1 (en) 2011-03-11 2017-05-03 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
US20150164955A1 (en) * 2012-07-19 2015-06-18 Reneuron Limited Stem cell microparticles
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
WO2014125277A1 (en) * 2013-02-12 2014-08-21 Reneuron Limited Method of producing microparticles
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
US20160193252A1 (en) * 2013-08-14 2016-07-07 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
CN103740645A (en) * 2013-12-06 2014-04-23 山西医科大学 Preparation of neural stem cell-derived Exosomes, and application of neural stem cell-derived Exosomes in nervous system diseases
JP6343671B2 (en) * 2013-12-12 2018-06-13 サムスン ライフ パブリック ウェルフェア ファウンデーション Method for promoting the generation of stem cell-derived exosomes using thrombin
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
JP6295341B2 (en) 2014-03-18 2018-03-14 サムソン ライフ パブリック ウェルフェア ファウンデーション Composition for treating brain inflammatory disease comprising stem cell-derived exosome as an active ingredient
CN103940998B (en) * 2014-05-04 2016-04-20 山东大学 The application of the early diagnosis marker that serum microRNA shifts as hepatocellular carcinoma
DK3145493T3 (en) 2014-05-18 2022-10-31 Childrens Medical Center METHODS AND COMPOSITIONS RELATING TO EXOSOMES
KR101593797B1 (en) * 2014-05-22 2016-02-12 가톨릭대학교 산학협력단 Pharmaceutical composition for treating or preventing diabetes mellitus comprising mir-137
KR101721492B1 (en) * 2014-05-26 2017-03-30 한국생명공학연구원 Pharmaceutical composition comprising expression or activity inhibitors of NDRG3 for the prevention and treatment of cancer
WO2015200851A1 (en) * 2014-06-27 2015-12-30 Inarian Neurodiagnostics, Llc Method for enriching cns-derived exosomes
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
ES2831298T3 (en) 2014-11-07 2021-06-08 Exocobio Inc Composition that includes exosomes derived from stem cells to whiten the skin or improve wrinkles
WO2016072821A1 (en) * 2014-11-07 2016-05-12 한양대학교 에리카산학협력단 Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement
WO2016083500A1 (en) * 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
WO2016082882A1 (en) * 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
ES2774456T3 (en) 2014-12-30 2020-07-21 Cell Cure Neurosciences Ltd RPE cell populations and methods of cell generation
WO2016186987A1 (en) * 2015-05-15 2016-11-24 Trustees Of Dartmouth College Biomarker micrornas and method for determining tumor burden
WO2017001649A1 (en) * 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
CN107849535B (en) 2015-08-03 2022-11-22 国立大学法人大阪大学 Exosomes derived from mesenchymal stem cells
US20170121685A1 (en) * 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
US20170119682A1 (en) * 2015-11-02 2017-05-04 Tigenix, S.A.U. Mesenchymal stem cell-derived exosomes and their uses
US11857575B2 (en) 2015-11-02 2024-01-02 Takeda Pharmaceutical Company Limited Mesenchymal stem cell-derived exosomes and their uses
CN108697740A (en) 2015-11-18 2018-10-23 佐治亚大学研究基金会 The outer vesica of nerve cell
CN106729750A (en) * 2015-11-20 2017-05-31 昆山彭济凯丰生物科技有限公司 Method and medicine and their application of high fat of blood, fatty liver, type-II diabetes and losing weight are treated by miR-183
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
CN109153968A (en) * 2016-04-12 2019-01-04 联合细胞Ev股份公司 Extracellular vesica (EV) is separated from biologicfluid sample
WO2017191234A1 (en) * 2016-05-06 2017-11-09 Unicyte Ev Ag Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
TWI601741B (en) 2016-07-11 2017-10-11 財團法人國家衛生研究院 Method of producing exosomes by using ep4-antagonist to induce exosomes releasing from stem cells and the use thereof
WO2018033911A1 (en) 2016-08-14 2018-02-22 Ramot At Tel-Aviv University Ltd. Mesenchymal cell-derived exosomes to treat neurological disorders
CN106367419A (en) * 2016-10-10 2017-02-01 徐州医科大学 Antisense oligonucleotide with neuroprotective effect, medicine composition and application thereof
CN107858424B (en) * 2016-11-24 2021-05-25 南华大学 Application of miRNA-4731-3p as primary lung cancer diagnosis marker
EP3600151A4 (en) * 2017-05-05 2021-01-13 Capricor, Inc. Methods of treating systemic graft-versus-host disease with extracellular vesicles
CN107243012B (en) * 2017-05-25 2020-01-24 江苏大学 Application of exosomes-loaded miR-93-5p in treatment of rheumatoid arthritis
KR102056172B1 (en) * 2017-12-06 2019-12-16 주식회사 디자인셀 Composition for treating or preventing arthritis comprising culture solution of stem cell-derived exosome
EP3731789A4 (en) * 2017-12-29 2021-09-08 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
KR102096150B1 (en) 2018-01-05 2020-04-02 재단법인 아산사회복지재단 Composition for Improving Skin Conditions, or Preventing or Treating Skin Diseases comprising Induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells pre-treated with Interferon-gamma, and Exosomes derived therefrom
CN112236131A (en) * 2018-03-29 2021-01-15 技术研究及发展基金有限公司 Vesicles comprising PTEN inhibitors and uses thereof
EP3773519A4 (en) * 2018-04-06 2021-12-29 Wisconsin Alumni Research Foundation Structured nanocoatings for the stabilization of pluripotent stem cell media components
KR102111025B1 (en) * 2018-06-05 2020-05-15 고려대학교 산학협력단 Cosmetic Composition for Anti-aging or Anti-wrinkles Comprising Neural Stem Cell Conditioned Medium and Method for Preparing the Same
CN109276575B (en) * 2018-07-23 2020-02-07 海南医学院 Application of miR-9 in preparation of medicine for treating acute coronary syndrome
CN112566626A (en) 2018-08-10 2021-03-26 欧姆尼斯普兰特有限公司 Extracellular vesicles for inhalation
CN113015794A (en) * 2018-10-12 2021-06-22 兰诺龙有限公司 Induced pluripotent cells comprising controllable transgenes for conditional immortalization
CN109234381B (en) * 2018-10-22 2021-06-18 云南省玉溪市人民医院 Application of miR-2682-5p as renal fibrosis marker
KR102320800B1 (en) * 2018-10-25 2021-11-02 사회복지법인 삼성생명공익재단 Stem cell-derived microvesicles with enhanced efficacy, use thereof and method for enhancing efficacy
US11351119B2 (en) 2018-10-25 2022-06-07 Samsung Life Public Welfare Foundation Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy
CN109680058A (en) * 2019-01-10 2019-04-26 华中科技大学同济医学院附属协和医院 Application and kit of the miR-101 level detection in diabetic microvascular complication diagnostic reagent
EP4219686A1 (en) * 2019-06-10 2023-08-02 Brexogen Inc. Composition for promoting production of stem cell-derived exosomes and increasing stemness
KR102159914B1 (en) * 2019-07-30 2020-09-24 주식회사 엑소코바이오 New method for producing exosomes and its application
US20210052641A1 (en) * 2019-08-23 2021-02-25 United Therapeutics Corporation Pre-conditioned extracellular vesicles and methods of production
CN110564682B (en) * 2019-09-30 2021-04-02 陕西中鸿科瑞再生医学研究院有限公司 Method for large-scale production of human adipose-derived mesenchymal stem cell exosomes
GB201919021D0 (en) 2019-12-20 2020-02-05 Reneuron Ltd Nucleic acid constructs for delivering polynucleotides into exosomes
EP4132479A1 (en) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
KR102319735B1 (en) * 2020-04-28 2021-11-01 건국대학교 산학협력단 A Method for Obtaining Extracellular Vesicles from 3-Dimensional Cultured Stem Cells
KR102184428B1 (en) * 2020-05-25 2020-11-30 주식회사 씨케이엑소젠 Method for preparing exosomes from mesenchymal stem cells and culture solution and culture solution produced from the same
CN111850047B (en) * 2020-07-28 2022-08-12 枣庄学院 miR-16 and miR-30c combined expression vector and construction method and application thereof
KR102284304B1 (en) 2020-11-05 2021-08-02 주식회사 타임바이오 Isolation method of progenitor cells using cold shock and method for producing exosome using these progenitor cells
WO2022114724A1 (en) * 2020-11-27 2022-06-02 (주)엑셀세라퓨틱스 Medium composition for producing exosome with high efficacy and high purity
WO2022204487A1 (en) * 2021-03-26 2022-09-29 Duke University Systems and methods for exosome delivery of micrornas for cellular reprogramming
US11613734B2 (en) 2021-06-11 2023-03-28 Fullstem Co., Ltd. Method of collecting for exosome
GB202114441D0 (en) 2021-10-08 2021-11-24 Reneuron Ltd Proteins and extracellular vesicles
KR20230129667A (en) * 2022-03-02 2023-09-11 서울대학교병원 Composition containing exosomes extracted from mesenchymal stem cells for preventing or treating retinal degeneration disease
JP7371975B1 (en) 2022-09-27 2023-10-31 セルソース株式会社 Method for producing extracellular vesicles and composition containing extracellular vesicles
WO2024089632A1 (en) * 2022-10-26 2024-05-02 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Composition of extracellular vesicles and uses thereof
CN116426648B (en) * 2023-03-27 2024-03-08 艾一生命科技(广东)有限公司 miRNA combination for identifying stem cell exosomes and qRCR primer thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CA2399434C (en) 2000-02-11 2010-10-19 The Schepens Eye Research Institute, Inc. Isolation and transplantation of retinal stem cells
PL1758986T3 (en) 2004-06-09 2016-03-31 Univ Court Univ Of Edinburgh Neural stem cells
EP1645626B1 (en) 2004-09-30 2007-09-12 Reneuron Limited Cell line
WO2006087233A2 (en) * 2005-02-21 2006-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells
US20070264712A1 (en) * 2006-01-10 2007-11-15 Theradigm, Inc. Expansion and differentiation of neural stem cells under low oxygen conditions
JP5718648B2 (en) 2008-02-22 2015-05-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） Mesenchymal stem cell particles
WO2010062706A2 (en) * 2008-10-30 2010-06-03 Caris Mpi, Inc. Methods for assessing rna patterns
KR101067742B1 (en) * 2009-01-05 2011-09-28 서울대학교산학협력단 Exosome derived from Human Neural Stme Cells with Immunomodulatory Effect and Immunomodulator comprising the same
WO2010119256A1 (en) * 2009-04-17 2010-10-21 Isis Innovation Limited Composition for delivery of genetic material
EP2448595B1 (en) * 2009-07-02 2017-06-14 ITH Immune Therapy Holdings AB Exosome based treatment of cancer
WO2011062244A1 (en) * 2009-11-18 2011-05-26 Kuroda Masahiko Carrier, method for producing same, and applications of same
WO2011069100A2 (en) * 2009-12-04 2011-06-09 Duke University Microrna and use thereof in identification of b cell malignancies
US9297007B2 (en) * 2010-05-28 2016-03-29 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg miRNAs involved in the blood brain barrier function
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
EP3412282A1 (en) * 2011-06-02 2018-12-12 The Regents of the University of California Membrane encapsulated nanoparticles and method of use
WO2013124816A2 (en) * 2012-02-22 2013-08-29 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons

Also Published As

Publication number Publication date
KR20150004822A (en) 2015-01-13
US20150079046A1 (en) 2015-03-19
US20190388475A1 (en) 2019-12-26
AU2013245406A1 (en) 2014-10-02
WO2013150303A1 (en) 2013-10-10
KR101993027B1 (en) 2019-09-30
CA2868506C (en) 2023-10-24
JP2019013234A (en) 2019-01-31
JP6644851B2 (en) 2020-02-12
JP6450673B2 (en) 2019-01-09
JP2022115954A (en) 2022-08-09
JP2015513906A (en) 2015-05-18
EP3470073A1 (en) 2019-04-17
EP2833893A1 (en) 2015-02-11
CA2868506A1 (en) 2013-10-10
AU2013245406B2 (en) 2017-07-20
CN104321062A (en) 2015-01-28
EP2833893B1 (en) 2018-08-29
ES2691296T3 (en) 2018-11-26
CN104321062B (en) 2018-09-25
JP2024073546A (en) 2024-05-29
JP2020072718A (en) 2020-05-14
BR112014024541A2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
SG11201500329WA (en) Stem cell microparticles
SG11201406336YA (en) Stem cell microparticles
HK1211623A1 (en) Cell lines
HK1209295A1 (en) Concentrator
SG11201503867WA (en) Structure
EP2857651A4 (en) Coolant-control valve
AU347859S (en) Battery
AU346864S (en) Battery
EP2824749A4 (en) Laminated-structure battery
SI2758523T1 (en) Stromal stem cells
EP2911230A4 (en) Cell
EP2939306A4 (en) Battery
EP2831949A4 (en) Sodium-oxygen cells
IL237228B (en) Stem cell enhancing therapeutics
EP2888513A4 (en) Pulse-width-regulating valve
PL2867530T3 (en) Tappet
GB201319035D0 (en) Spolier structure
EP2821614A4 (en) Valve
SI2904319T1 (en) Thermostic valve
EP2939294A4 (en) Battery
EP2863459A4 (en) Flat cell
HUP1300640A2 (en) Belt-mounting structure
EP2871919A4 (en) Structure
HUP1200436A2 (en) Valve arrangement
GB201203255D0 (en) Valve